Specify a stock or a cryptocurrency in the search bar to get a summary
Sareum Hldgs Plc
SARSareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor that is in a Phase 1a clinical trials for the treatment of autoimmune diseases. Its also developing SDC-1802, a TYK2/JAK1 inhibitor, which is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage, oral, selective Checkpoint kinase 1 (Chk1) inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms. The company was incorporated in 2004 and is headquartered in Cambridge, the United Kingdom. Address: Langford Arch, Cambridge, United Kingdom, CB22 3FX
Analytics
WallStreet Target Price
138.53 GBPP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures SAR
Dividend Analytics SAR
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History SAR
Stock Valuation SAR
Financials SAR
Results | 2019 | Dynamics |